Featured Research

from universities, journals, and other organizations

UT Southwestern Initiating Trials In Humans For Ricin Vaccine

Date:
December 10, 2004
Source:
University Of Texas Southwestern Medical Center At Dallas
Summary:
A potential vaccine for the deadly toxin ricin, a "Category B" biological agent, will enter the first phase of clinical testing in coming weeks at UT Southwestern Medical Center at Dallas.

DALLAS – Nov. 30, 2004 – A potential vaccine for the deadly toxin ricin, a "Category B" biological agent, will enter the first phase of clinical testing in coming weeks at UT Southwestern Medical Center at Dallas.

Related Articles


The Food and Drug Administration and the UT Southwestern Institutional Review Board have agreed that the trial can go forward in humans.

"This is a safety and immunogenicity trial," said Dr. Ellen Vitetta, director of the Cancer Immunobiology Center at UT Southwestern. "To test the immune response induced by the vaccine, the sera (blood products) from our injected human volunteers will be tested for levels of specific ricin-neutralizing antibodies. These antibodies, in turn, will be evaluated for their ability to protect mice against a lethal ricin challenge. As far as we can tell, the vaccine is completely safe and has no side effects."

Dr. Vitetta's work with ricin received international attention when she and a team of UT Southwestern researchers developed an experimental vaccine for the deadly toxin as an outgrowth of their cancer-therapy work. The translation from discovery to clinical testing has moved rapidly with support from the National Institutes of Health (NIH) and the "incredible efforts of a talented and dedicated group of scientists and research associates," Dr. Vitetta said.

The genetically engineered protein vaccine, RiVax, was developed by Dr. Vitetta and the center's Drs. Victor Ghetie, professor; Joan Smallshaw, assistant professor; and John Schindler, assistant professor and director of the clinical trial.

Ricin, which can be administered in foods and water or sprayed as an aerosol, is extracted from castor beans. There is currently no effective vaccine or treatment for ricin poisoning in humans.

Depending on how the ricin is administered, victims develop fever, nausea and abdominal pain or lung damage before dying within a few days of exposure. There is no antidote after the first few hours of exposure, and because symptoms do not appear until later and often mimic other illnesses, individuals often do not know if they have been exposed until it is too late for treatment, Dr. Vitetta said.

Because castor beans are readily available, public health officials warn that ricin could be used for terrorism. Indeed, ricin has a long history of use in espionage, and there have been several recent incidents involving the toxin in the United States and Europe. The Centers for Disease Control classifies ricin as a "Category B" biological agent, which means it is "relatively easy to disseminate."

In creating the new vaccine, Dr. Smallshaw mutated the DNA encoding the active "A" chain of the toxin. She deleted the site in this chain that inhibits the cell's ability to synthesize proteins, as well as the site responsible for inducing vascular leak in the host. UT Southwestern scientists eventually created three genetically distinct non-toxic versions of the ricin A chain, two of which were effective as vaccines in mice. Dr. Vitetta said E. coli bacteria are used to produce the A chain protein, making vaccine production inexpensive and safe.

The DNA sequence was identified by Dr. Vitetta's group several years ago in its ongoing efforts to produce safer immunotoxins containing the A chain of ricin. Dr. Vitetta and her colleagues have used such immunotoxins – anti-cancer drugs – as experimental therapy in more than 300 cancer patients.

Injected RiVax protects mice against 10 lethal doses of ricin and has no side effects in mice when given at 100 times the dosage required for an immune response. A similar study in rabbits also showed no side effects, and the animals also produced high levels of ricin-neutralizing antibodies, Dr. Vitetta said.

The pilot phase I trial – to be carried out by Dr. Robert Munford, professor of internal medicine and microbiology – is designed to confirm the vaccine's safety at doses that induce effective antibody levels in healthy humans. DOR BioPharma, Inc. has received an exclusive license for the vaccine and is developing manufacturing processes for the genetically engineered vaccine. DOR is planning to produce a large stockpile for more advanced human clinical testing, product licensing and potential purchases from the U.S. government and other interested parties.

"I am confident that DOR will move the vaccine forward rapidly and effectively after our trial is completed, assuming that the vaccine is safe," Dr. Vitetta said.

"Our future work here at UT Southwestern will focus on how to deliver the vaccine by oral or intranasal routes instead of by injection," she said. "Mucosal immunity is fascinating and extremely important for virtually all types of biothreats because most will be inhaled or ingested. It is important to have immunity at these anatomical sites and not only in the blood. The blood may prevent death but not tissue damage in the lungs, intestine and elsewhere."


Story Source:

The above story is based on materials provided by University Of Texas Southwestern Medical Center At Dallas. Note: Materials may be edited for content and length.


Cite This Page:

University Of Texas Southwestern Medical Center At Dallas. "UT Southwestern Initiating Trials In Humans For Ricin Vaccine." ScienceDaily. ScienceDaily, 10 December 2004. <www.sciencedaily.com/releases/2004/11/041130204210.htm>.
University Of Texas Southwestern Medical Center At Dallas. (2004, December 10). UT Southwestern Initiating Trials In Humans For Ricin Vaccine. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2004/11/041130204210.htm
University Of Texas Southwestern Medical Center At Dallas. "UT Southwestern Initiating Trials In Humans For Ricin Vaccine." ScienceDaily. www.sciencedaily.com/releases/2004/11/041130204210.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins